Tag: Onasemnogene abeparvovec

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Onasemnogene abeparvovec

Millennium Management Llc Decreased Atricure (Call) (ATRC) Stake By $22.30 Million; First Allied ...

Added to Collection on: 2019-05-18 19:38:42

Tags for this article:

Health sciences
Life Sciences
Companies
Spinal muscular atrophy
Novartis
NVS
Onasemnogene abeparvovec
Millennium Management Llc
NASDAQ

Click the tags to see associated articles and topics

View Article Details
'You Cannot Put A Price On Your Child's Life': Families Push Back On Criticism Over $2.1M Drug

Added to Collection on: 2019-06-02 20:45:00

Tags for this article:

Health
Pharmaceutical industry
Novartis
Spinal muscular atrophy
Life Sciences
Medication
Onasemnogene abeparvovec

Click the tags to see associated articles and topics

View Article Details
Former AveXis executives launch gene therapy startup with uncommon targets

Added to Collection on: 2021-02-25 12:00:00

Tags for this article:

Branches of biology
Life Sciences
Health sciences
Spinal muscular atrophy
Applied genetics
Drug discovery
Gene therapy
Emerging technologies
AveXis
Adeno-associated virus
Novartis
Onasemnogene abeparvovec
Sean Nolan

Click the tags to see associated articles and topics

View Article Details
The UK's National Health Service just approved a drug that costs nearly $2.5 million a dose

Added to Collection on: 2021-03-08 14:33:48

Tags for this article:

Branches of biology
Life Sciences
Neurological disorders
Spinal muscular atrophy
Breakthrough therapy
Gene therapy
Orphan drugs
Novartis Gene Therapies
Biotechnology
Onasemnogene abeparvovec
Novartis
National Health Service

Click the tags to see associated articles and topics

View Article Details
Double first for Scotland as it backs Roche's Rozlytrek, Novartis' Zolgensma

Added to Collection on: 2021-03-09 10:52:30

Tags for this article:

Branches of biology
Orphan drugs
Health sciences
Chemical compounds
Breakthrough therapy
Tyrosine kinase receptors
Entrectinib
Piperazines
ROS1
Onasemnogene abeparvovec
Gene therapy
Larotrectinib
Roche Products Ltd.

Click the tags to see associated articles and topics

View Article Details
RPT-UPDATE 1-Roche, Novartis approvals in Europe signal more head-to-head competition

Added to Collection on: 2021-03-30 06:33:45

Tags for this article:

Life Sciences
Health sciences
Spinal muscular atrophy
Neurological disorders
Orphan drugs
Breakthrough therapy
Novartis
Onasemnogene abeparvovec
Gene therapy
Nusinersen
Risdiplam
Ocrelizumab
United States
Roche

Click the tags to see associated articles and topics

View Article Details
Zolgensma flatlines, but Spinraza isn't the beneficiary

Added to Collection on: 2021-04-27 15:00:00

Tags for this article:

Life Sciences
Spinal muscular atrophy
Health sciences
Branches of biology
Novartis Gene Therapies
Onasemnogene abeparvovec
Novartis
Gene therapy
Nusinersen
Biogen
Intrathecal administration
United States

Click the tags to see associated articles and topics

View Article Details
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up

Added to Collection on: 2021-06-18 19:52:30

Tags for this article:

Spinal muscular atrophy
Branches of biology
Life Sciences
Neurological disorders
Orphan drugs
Biotechnology
Novartis Gene Therapies
Gene therapy
Novartis
Onasemnogene abeparvovec
Risdiplam
Nusinersen

Click the tags to see associated articles and topics

View Article Details
Roche and Biogen-sponsored SMA walk events roll on virtually through the pandemic

Added to Collection on: 2021-07-01 15:00:00

Tags for this article:

Life Sciences
Spinal muscular atrophy
Health sciences
Neurological disorders
Orphan drugs
Nusinersen
Biogen
Onasemnogene abeparvovec
Genentech
Novartis
Gene therapy
Risdiplam
Cure SMA

Click the tags to see associated articles and topics

View Article Details
Book a Demo